Feed TMDX
TM

TransMedics TMDX · NASDAQ

$65.99 -1.68% (-$1.13)

Market cap
$2.33B
Enterprise value
$2.72B
P/E
15.3x
Forward P/E
39.9x
PEG
0.0x
P/S
3.5x
P/FCF
29.4x
EV/EBITDA
22.7x
ROIC
12.3%
Gross margin
58.7%
Net margin
22.7%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
3.3x
Beta
1.93
Free float
96.8%

About the company

TransMedics Group, Inc. (TMDX) is an American company specializing in the development and manufacturing of innovative medical devices for organ transplantation. With the aim of improving the preservation and transportation of organs intended for transplantation, TransMedics has developed the Organ Care System (OCS) technology. This technology allows organs to be maintained in optimal condition during transportation, potentially increasing the success of transplant procedures. The company is known for its commitment to saving lives and innovations in the field of organ transplantation. TransMedics Group, Inc. (TMDX) shares could be suitable for investors looking to invest in a company actively supporting medical research and life-saving through organ transplantation.

Sector

Healthcare

Industry

Medical - Devices

CEO

Waleed H. Hassanein

Employees

898

Headquarters

Andover

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 86% a year over the last 3 years.
  • What speaks for it: Analysts expect revenue to grow by 23% this fiscal year.
  • What to watch: It missed profit estimates 4 times in the last 8 quarters.
  • What to watch: Earnings per share swing sharply from year to year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 23 USD is left as net profit.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy